Jevtana Approval History
Jevtana (cabazitaxel) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
Development History and FDA Approval Process for Jevtana
|Jun 17, 2010||Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.